Prevalence of Candidate Vaccine Targets and Genomic Features of Pediatric Invasive Streptococcus Agalactiae in Japan - Takeaways - MDSpire

Prevalence of Candidate Vaccine Targets and Genomic Features of Pediatric Invasive Streptococcus Agalactiae in Japan

  • By

  • Masashi Kasai

  • Satoshi Nakano

  • Shota Koide

  • Shogo Otake

  • Meiwa Shibata

  • Kasumi Ishida-Kuroki

  • Yo Sugawara

  • Yukihiro Akeda

  • Kandai Nozu

  • Motoyuki Sugai

  • October 9, 2025

  • 0 min

Share

  • 1

    Streptococcus agalactiae is a major cause of invasive infections in neonates, leading to significant morbidity and mortality.

  • 2

    The study analyzed 237 GBS isolates from children in Japan, revealing high vaccine coverage rates of 98.3% and 94.9% for two vaccine candidates.

  • 3

    Resistance to erythromycin and clindamycin was found in 61.2% and 43.5% of isolates, indicating a concerning trend in antimicrobial resistance.

  • 4

    Genomic analysis identified a predominant multidrug-resistant clone within the CC17 lineage, highlighting persistent regional circulation.

  • 5

    The findings underscore the need for further investigation into GBS transmission routes and the development of effective maternal vaccines.

Original Source(s)

Prevalence of Candidate Vaccine Targets and Genomic Features of Pediatric Invasive Streptococcus Agalactiae in Japan

  • by Masashi Kasai, Satoshi Nakano, Shota Koide, Shogo Otake, Meiwa Shibata, Kasumi Ishida-Kuroki, Yo Sugawara, Yukihiro Akeda, Kandai Nozu, Motoyuki Sugai

  • October 9, 2025

Related Content

Identification of clinical phenotypes and prediction model for the mixed-infection phenotype of pediatric community-acquired pneumonia based on unsupervised machine learning

AAE Revises Dental Trauma Guidance

Recommendations outline splinting, replantation timing, imaging, and long-term surveillance strategies for permanent tooth injuries.

Antibiotics May Not Help Mild COVID

A retrospective cohort study of more than 520,000 hospitalized patients found no clinically meaningful improvement in deterioration or mortality with early treatment targeting community-acquired pneumonia.